今日（7月23日）A股市场收盘共58股涨停，剔除7只ST板块个股后，51股涨停；56股封板未遂，整体封板率为50.88%。 （原标题：揭秘涨停丨3连板！超50亿元资金抢筹雅下水电龙头股） 涨停战场： 中国电建封单资金超50亿元 据证券时报·数据宝统计，从收盘涨停板封单量来看，中国电建封单量最高，有750.33万手；其次是西藏天路、铁建重工、中铁工业，涨停板封单 分别为206.45万手、182.56万手、95.11万手。 从连续涨停天数来看，南矿集团4连板，中国电建、西藏天路、铁建重工等29股3连板，*ST南置2连板。 以封单金额计算，20股封单资金均超1亿元，中国电建、西藏天路、铁建重工封单资金居前，分别为50.8亿元、26.32亿元、13亿元。 中国电建为雅下水电热门龙头股。年报显示，公司2024年新签水电业务1428.96亿元，占能源电力业务比例为18.73%，同比增长26.35%。作为水 电、抽水蓄能建设领域的绝对主力，公司中标/新签了浙江建德抽水蓄能项目EPC总承包（81.7亿元）、肃南皇城抽水蓄能项目EPC总承包（81.3亿 元）、富民抽水蓄能项目EPC总承包（64亿元）等项目。 龙头点睛： 雅下水 ...

炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 2025年6月，济川药业实控人曹龙祥将其持有的济川控股10.10%股权以1010万元价格转让给儿子曹飞， 曹飞通过济川控股、西藏济川企业管理有限公司间接控制上市公司56.07%股权，触发全面要约收购义 务。然而，在预存18.95亿元保证金（相当于最高收购总额94.48亿元的20%）后，最终仅0.1%的流通股 份接受要约。 耗资不菲的交班仪式背后，济川药业正面临核心产品全线失速、研发投入失衡、高额分红侵蚀未来竞争 力的三重困局。此前，曹飞曾个人出资5亿元溢价54%收购万鸿集团，展现出其资本运作手腕，接班济 川药业后，其能否带领企业穿越寒冬？ 近19亿元巨额保证金仅换来34户股东响应，这戏剧性一幕发生在儿科中药龙头济川药业的控制权交接现 场。 核心产品集体"熄火" 从财务数据看，2024年济川药业实现营收80.17亿元，同比下降16.96%；归母净利润为25.32亿元，同比 下滑10.32%。2025年一季度，公司业绩进一步下滑，当期营收15.25亿元，同比下降36.51%；归母净利 润4.4亿元，同比下降47.91%，几近腰斩。 结合产品 ...

（原标题：揭秘涨停丨最高8连板，这些牛股获资金追捧） 今日（7月18日），A股市场收盘共52股涨停，剔除掉6只ST板块个股后，有46股涨停，21股封板未遂，整体封板率为71.23%。 涨停战场：上纬新材封单资金超9亿元 从收盘涨停板封单量来看，人民同泰封单量最高，有39.36万手；其次是上纬新材、美邦股份、中色股份、延华智能，涨停板封单分别为28.07万 手、22.24万手、22.09万手、18.11万手。 从连续涨停天数来看，上纬新材8连板，兰生股份6连板，*ST恒久5连板，天宸股份、海星股份、*ST威尔3连板，人民同泰、美邦股份、延华智能 等8股2连板，柳钢股份4日3板等。 以封单金额计算，13股封单资金超1亿元，上纬新材、美邦股份、人民同泰封单资金居前，分别为9.39亿元、5.19亿元、3.64亿元。 涨停个股：金圆股份、国机通用、久吾高科、盛新锂能 7月18日碳酸锂期货2509合约上涨2.82%，近20个交易日上涨17.42%。 金圆股份：公司捌千错盐湖提锂项目处于试生产阶段。 国机通用：公司开发研制出的三元锂电池材料过滤洗涤一体机，在多家锂电材料生产企业应用。 久吾高科：公司现有的盐湖提锂产品及技术 ...

Group 1 - The company expects a net loss for the period from January 1, 2025, to June 30, 2025, with an estimated loss ranging from 30 million to 39 million yuan, compared to a profit of 37.8015 million yuan in the same period last year, representing a decline of 179.36% to 203.17% [1] - The company anticipates a net profit attributable to shareholders of the listed company to be between a loss of 38 million to 46 million yuan, with a significant decrease in net profit after deducting non-recurring gains and losses, expected to be a loss of 38 million to 46 million yuan compared to a profit of 31.4786 million yuan last year, reflecting a decline of 220.72% to 246.13% [1] - Basic earnings per share are projected to be a loss of 0.09 to 0.12 yuan per share, compared to a profit of 0.11 yuan per share in the previous year [1] Group 2 - The main reasons for the performance decline include the impact of pharmaceutical industry policies and market factors, particularly the national centralized procurement policy, which led to a significant decrease in sales volume of the main profit-generating product, Rabeprazole Sodium Enteric-coated Capsules, as well as varying impacts on sales volume and prices of other major formulation products, resulting in a decline in gross profit [1] - The sales prices of major raw materials have also significantly decreased due to domestic and international market competition, contributing to a decline in both operating revenue and product profitability compared to the previous year [1]

Core Viewpoint - Jichuan Pharmaceutical is facing significant challenges with declining sales and profits from its core products, leading to a search for new growth opportunities through innovative drug development [2][10]. Group 1: Company Performance - Jichuan Pharmaceutical's revenue and net profit are projected to decline in 2024, with a revenue drop of 16.96% to 8.017 billion yuan and a net profit decrease of 10.32% to 2.532 billion yuan [6][7]. - The company's flagship product, Pudilan Anti-inflammatory Oral Liquid, has seen a significant decline in sales due to regulatory changes and removal from various medical insurance lists, contributing to the overall revenue drop [4][6]. - The sales volume of Pudilan Anti-inflammatory Oral Liquid fell by 24% in 2019 compared to the previous year, marking the first decline in revenue and net profit since its listing [4]. Group 2: Product Challenges - The core product, Rebeprazole Sodium Enteric-coated Capsules, has been impacted by price reductions due to national procurement policies, leading to a significant drop in market share and sales [8][10]. - Pediatric product, Xiaer Chiqiao Qingre Granules, is also experiencing sluggish growth, further straining the company's revenue [8][10]. Group 3: Innovation and Future Prospects - Jichuan Pharmaceutical is pinning hopes on the innovative drug Xiaer Biantong Granules, which has received a notice of acceptance for market application, potentially filling a gap in the pediatric constipation treatment market [2][10]. - The company has invested approximately 51.42 million yuan in the development of Xiaer Biantong Granules, which is based on a patented formula aimed at treating pediatric constipation [10][12]. - Other innovative drugs in development include a flu treatment and a long-acting growth hormone, both of which have received regulatory acceptance [12]. Group 4: R&D Investment - Jichuan Pharmaceutical has been criticized for its historically low R&D investment, which was only 5.55% of total revenue in 2024, compared to over 8% for some competitors [12][13]. - The company’s sales expenses were significantly higher at 36.85% of total revenue, indicating a need for a more balanced approach between marketing and research and development [12].

证券代码：002923 证券简称：润都股份 珠海润都制药股份有限公司 答：公司始终秉持"规范、专业、发展"的理念，以专注铸就卓越，以技 术引领未来。积极推动绿色化和合成生物技术的应用，加速仿制药与创新 药的研发与上市。公司将顺应医药行业发展趋势，重点围绕心脑血管、消 化系统、解热镇痛、手术麻醉用药等领域，做优做强制剂产业，持续保持 独具特色的药物新剂型和肠溶、 缓控释制剂技术优势，加快高技术壁垒 仿制药和原创新药研发上市，拓展全渠道终端，打造立体品牌。 6、原料药沙坦类价格趋势？ 答：随着公司全球化销售网络的稳步推进，大客户项目持续转化落地，沙 坦类产品销量不断攀升，进一步夯实了公司沙坦类产品的市场竞争力；受 供需关系等多重因素影响，沙坦类产品市场竞争依然激烈，市场销售价格 仍在低位区间波动。 | 关于本次活动 是否涉及应披 | | | --- | --- | | | 无 | | 露重大信息的 | | | 说明 | | | 附件清单 | 无 | | （如有） | | | | □特定对象调研 □分析师会议 | | --- | --- | | 投资者关系活 | □媒体采访 □业绩说明会 | | 动类别 | □新闻 ...

Group 1 - The core point of the news is the announcement of a family internal equity structure adjustment at Jichuan Pharmaceutical, which triggers a mandatory general offer for the company's shares by Cao Fei, the son of the actual controller, Cao Longxiang [1][2] - On June 11, Cao Longxiang transferred 10.10% of his shares in Jichuan Holdings to Cao Fei for 10.1 million yuan, resulting in Cao Fei holding 60% of Jichuan Holdings and indirectly controlling 5.17 billion shares of Jichuan Pharmaceutical, which is 56.07% of the total share capital [1] - The general offer price is set at 26.93 yuan per share, requiring a maximum total funding of 9.448 billion yuan, with the offer period lasting from June 18, 2025, to July 17, 2025 [2] Group 2 - Jichuan Pharmaceutical's major shareholder structure remains unchanged after the transfer, with Jichuan Holdings holding 4.17 billion shares, accounting for 45.22% of the total share capital, and the combined holdings of the controlling shareholder and concerted parties reaching 61.15% [1] - The company reported a revenue of 1.525 billion yuan in the first quarter of 2025, a year-on-year decrease of 36.51%, and a net profit attributable to shareholders of 440 million yuan, down 47.91% year-on-year [3] - The decline in revenue is attributed to two main factors: a high base in the first quarter of 2024 and the impact of centralized procurement on the main product, Rabeprazole Sodium Enteric-coated Capsules [3]

Group 1 - Health元 announced that its subsidiary, Lijuz Group, plans to acquire 64.81% of Imexpharm Corporation for approximately 5.73 trillion VND (about 1.587 billion RMB), which represents 11.45% of Lijuz Group's latest audited net assets [1] - Imexpharm Corporation is a Vietnamese pharmaceutical company engaged in the research, production, and sales of drugs, including antibiotics and cardiovascular medications [1] - After the acquisition, Imexpharm will become a subsidiary of Lijuz Group, aiding in the expansion of the group's overseas market [1] Group 2 - Lijuz Group's revenue has been under pressure, with a reported revenue of 11.812 billion RMB in 2024, a decrease of 4.97% year-on-year, while net profit increased by 5.50% to 2.061 billion RMB [2] - The decline in revenue is attributed to price reductions from national medical insurance negotiations affecting key products, as well as decreased sales in antiviral products following reduced demand due to COVID-19 and flu [2] - Health元 also reported a revenue of 15.619 billion RMB in 2024, down 6.17% year-on-year, with a net profit of 1.387 billion RMB, a decrease of 3.90% [2] Group 3 - Lijuz Group is accelerating its international expansion to enhance its risk resilience, with products already covering Southeast Asia, South America, the Middle East, and Africa [3] - The company has initiated the construction of an active pharmaceutical ingredient factory in Indonesia to support local and international production, aiming to reduce costs and improve market responsiveness [3] - In 2024, Lijuz Group achieved overseas revenue of 1.724 billion RMB, a year-on-year increase of 9.69%, accounting for 14.59% of total revenue, which is a 2 percentage point increase from 2023 [3]

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：600774 股票简称：汉商集团 编号：2025-031 汉商集团股份有限公司 关于2024年度暨2025年第一季度业绩说明会 召开情况的公告 本公司及董事会全体成员保证公告内容不存在虚假记载、误导性陈述或者重大遗漏，并对其内容的真 实、准确和完整承担法律责任。 （2）全覆盖的销售体系。在医药医疗板块，公司根据市场趋势、政策导向、技术应用、客户需求等， 精心培养营销人员，组建了400余人的销售精英团队，遍布全国31个省、市、自治区，触达医院、零售 药店、基层医疗机构、诊所、电商平台等各类销售渠道。营销人员通过提供专业的服务，向市场精准传 达公司产品知识和优势，产品成功落地国内公立及民营医院已超1万家；同时加快零售端和三终端的渠 道布局，目前已覆盖连锁药店门店近30万家，诊所超2万家。建立处方药的学术推广模式和电商业务旗 舰店，以C端为重心，B端为辅助，聚焦核心客户突出重点合作，发挥团队的专业化能力。 （3）专业化的研发平台。公司始终坚持技术创新驱动理念，在药品和医疗器械两个领域建立专业的研 发平台，长期为实现技术研发创新、加快成果转化及产业化、培养研 ...

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected price increase of over 15% in the next 6-12 months [5][13]. Core Insights - The company reported a revenue of 8.017 billion RMB in 2024, a decrease of 17% year-on-year, and a net profit attributable to shareholders of 2.532 billion RMB, down 10% year-on-year [2]. - In Q1 2025, the company achieved a revenue of 1.525 billion RMB, reflecting a 37% decline year-on-year, with a net profit of 440 million RMB, down 48% year-on-year [2]. - The company's core products faced pressure due to high base effects and centralized procurement policies, particularly impacting key products like Pudilan and pediatric medications [3]. - The company has made progress in product introductions, securing four new product agreements, which are expected to support long-term growth [3]. - The company has a strong cash position with over 12.5 billion RMB in cash and financial assets, and it plans to distribute a cash dividend of 2.09 RMB per share, totaling approximately 1.922 billion RMB, which is 75.93% of the net profit for 2024 [4]. Financial Forecasts - Revenue forecasts for 2025 and 2026 have been revised down to 7.421 billion RMB and 8.139 billion RMB, respectively, with net profit estimates adjusted to 2.263 billion RMB and 2.557 billion RMB [5]. - The expected earnings per share (EPS) for 2025, 2026, and 2027 are projected to be 2.456 RMB, 2.774 RMB, and 3.126 RMB, respectively, with corresponding price-to-earnings (P/E) ratios of 10, 9, and 8 times [5].